153 related articles for article (PubMed ID: 35577765)
1. Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy.
Cho J; Tae N; Ahn JH; Chang SY; Ko HJ; Kim DH
Biomol Ther (Seoul); 2022 Sep; 30(5):418-426. PubMed ID: 35577765
[TBL] [Abstract][Full Text] [Related]
2. LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8
Kim A; Han CJ; Driver I; Olow A; Sewell AK; Zhang Z; Ouyang W; Egen JG; Yu X
J Immunol; 2019 Aug; 203(4):1076-1087. PubMed ID: 31253728
[TBL] [Abstract][Full Text] [Related]
3. BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors.
Huang SW; Pan CM; Lin YC; Chen MC; Chen Y; Jan CI; Wu CC; Lin FY; Wang ST; Lin CY; Lin PY; Huang WH; Chiang YT; Tsai WC; Chiu YH; Lin TH; Chiu SC; Cho DY
Adv Sci (Weinh); 2023 Jun; 10(17):e2206856. PubMed ID: 37078788
[TBL] [Abstract][Full Text] [Related]
4. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
5. Microenvironment-responsive anti-PD-L1 × CD3 bispecific T-cell engager for solid tumor immunotherapy.
Liu D; Bao L; Zhu H; Yue Y; Tian J; Gao X; Yin J
J Control Release; 2023 Feb; 354():606-614. PubMed ID: 36669532
[TBL] [Abstract][Full Text] [Related]
6. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
7. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint.
Koopmans I; Hendriks D; Samplonius DF; van Ginkel RJ; Heskamp S; Wierstra PJ; Bremer E; Helfrich W
Oncoimmunology; 2018; 7(8):e1466016. PubMed ID: 30221065
[TBL] [Abstract][Full Text] [Related]
8. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
9. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors.
Xiao Y; Chen P; Luo C; Xu Z; Li X; Liu L; Zhao L
Cancer Treat Res Commun; 2021; 29():100467. PubMed ID: 34598062
[TBL] [Abstract][Full Text] [Related]
11. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
[TBL] [Abstract][Full Text] [Related]
12. Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Sam J; Colombetti S; Fauti T; Roller A; Biehl M; Fahrni L; Nicolini V; Perro M; Nayak T; Bommer E; Schoenle A; Karagianni M; Le Clech M; Steinhoff N; Klein C; Umaña P; Bacac M
Front Oncol; 2020; 10():575737. PubMed ID: 33330050
[TBL] [Abstract][Full Text] [Related]
13. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
Jeong S; Park E; Kim HD; Sung E; Kim H; Jeon J; Kim Y; Jung UJ; Son YG; Hong Y; Lee H; Lee S; Lim Y; Won J; Jeon M; Hwang S; Fang L; Jiang W; Wang Z; Shin EC; Park SH; Jung J
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230109
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1.
Ramaswamy M; Kim T; Jones DC; Ghadially H; Mahmoud TI; Garcia A; Browne G; Zenonos Z; Puplampu-Dove Y; Riggs JM; Bhat GK; Herbst R; Schofield DJ; Carlesso G
Cancer Immunol Res; 2022 Feb; 10(2):200-214. PubMed ID: 34937728
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
16. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
17. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
Zhai T; Wang C; Xu Y; Huang W; Yuan Z; Wang T; Dai S; Peng S; Pang T; Jiang W; Huang Y; Zou Y; Xu Y; Sun J; Gong X; Zhang J; Tsun A; Li B; Miao X
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172514
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy.
Ostrand-Rosenberg S; Horn LA; Ciavattone NG
Front Oncol; 2019; 9():215. PubMed ID: 31001479
[TBL] [Abstract][Full Text] [Related]
19. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
[TBL] [Abstract][Full Text] [Related]
20. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J
Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
